Pharmacological Spectrum of Gymnema sylvestre, Cuminum cyminum, and Allium sativum: Evidence from In Vivo, In Vitro, and In Silico Studies Relevant to Nicotine-Induced Insulin Resistance and Hyperlipidemia

Abstract

Background:The chronic smoking induced by nicotine induces insulin resistance, dyslipidemia, oxidative stress, and metabolic dysfunction. In this regard, herbal agents, including Gymnema sylvestre (GS), Cuminum cyminum (CC), and Allium sativum (AS), contain bioactive compounds that may attenuate these pathways. A cohesive perspective on their mechanistic effects in different experimental models must be derived.

Objective:
To collate evidence obtained from in vivo, in vitro, and in silico studies, evaluating pharmacological actions of GS, CC, and AS toward insulin resistance and hyperlipidemia, with a contribution to studies of nicotine-associated metabolic disturbances.

Methods: We assessed forty-six studies in validated diabetic, hyperlipidemic, metabolic syndrome, obesity, oxidative stress, and organ-specific models. Extracts, standardized phytoconstituents (gymnemic acids, gymsylosides), isolated compounds (cuminaldehyde, S-allylcysteine), and nano-formulations were evaluated for their metabolic, antioxidant, and molecular effects.

Results: GS exhibited persistent antihyperglycemic, antihyperlipidemic, anti-obesity, immunomodulatory, and cytoprotective actions. Among these, active pathways included stimulating PI3K/Akt and AMPK, β-cell regeneration, inhibition of pancreatic lipase, autophagy initiation, and transcriptional modulation of metabolic genes. CC exerted significant antioxidant, antiglycating, insulinotropic, and lipid-lowering effects and protected β-cells and modified oxidative balance relevant to nicotine-induced metabolic stress. AS and its derivatives improved insulin sensitivity, corrected dyslipidemia, reduced oxidative and inflammatory markers, enhanced mitochondrial function, and modulated SIRT-3 pathways supporting cardiac, hepatic, and metabolic protection.

Conclusion: GS, CC, and AS demonstrate beneficial pharmacological roles aimed to antagonize mechanisms responsible for nicotine-induced insulin resistance and hyperlipidemia. Their regulation of glucose–lipid metabolism, oxidative stress, and inflammation indicates that they may serve as adjunct phytotherapeutic agents in smokers with high metabolic risk. It is therefore important that there is clinical validation in nicotine-exposed populations.